<DOC>
	<DOCNO>NCT00765115</DOCNO>
	<brief_summary>To test LY450139 , gamma-secretase inhibitor , reduce rate newly synthesize Amyloid Beta determine amount newly synthesize 13C6 leucine-labeled Amyloid Beta lumbar cerebrospinal fluid LY450139 treat subject compare placebo treated subject .</brief_summary>
	<brief_title>A Study Healthy Subjects Assess Effect LY450139 Amyloid Beta Peptide Production Rate Dose Response .</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Healthy volunteer : Men within age 21 50 Have serious unstable medical condition Have history serious infection affect brain head trauma result protracted loss consciousness within last 5 year multiple episode head trauma Have history primary recurrent malignant disease Have recent laboratory result indicate clinically significant laboratory abnormality determine investigator Have history chronic alcohol drug abuse within past 5 year Have know history Human immunodeficiency virus ( HIV ) , afebrile seizure , clinically significant multiple drug allergy Are judge clinically investigator serious risk suicide Have electrocardiogram abnormality obtain visit 1 opinion investigator clinically significant Use prescription counter medication safely discontinue within 14 day prior visit 2 Have criterion would preclude LP allergy local anesthetic ; local infection site LP medical condition require treatment warfarin heparin . Have receive treatment within last 30 day drug receive regulatory approval indication time study entry . Are investigator site personnel directly affiliate study immediate family . Are Lilly employee</criteria>
	<gender>Male</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>September 2008</verification_date>
</DOC>